Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MGMT and Whole-Genome DNA Methylation Impacts on Diagnosis, Prognosis and Therapy of Glioblastoma Multiforme.

International journal of molecular sciences - 27 Jun 2022

Della Monica Rosa, Cuomo Mariella, Buonaiuto Michela, Costabile Davide, Franca Raduan Ahmed, Del Basso De Caro Marialaura, Catapano Giuseppe, Chiariotti Lorenzo, Visconti Roberta

Abstract excerpt

Epigenetic changes in DNA methylation contribute to the development of many diseases, including cancer. In glioblastoma multiforme, the most prevalent primary brain cancer and an incurable tumor with a median survival time of 15 months, a single epigenetic modification, the methylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene, is a valid biomarker for predicting response to therapy with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Glioblastoma

Share to Isocitrate Dehydrogenase

Share to O(6)-Methylguanine-DNA Methyltransferase

Share to Tumor Suppressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 35806153
DOI: 10.3390/ijms23137148
PMCID: PMC9266959

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MGMT and Whole-Genome DNA Methylation Impacts on Diagnosis, Prognosis and Therapy of Glioblastoma Multiforme.PMID 35806153Read ↗

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challengesSemantic proximity Read ↗

Personalized treatment strategies in glioblastoma: MGMT promoter methylation statusSemantic proximity Read ↗

Epigenetic alterations in glioblastomas: Diagnostic, prognostic and therapeutic relevance.Semantic proximity Read ↗

MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?Semantic proximity Read ↗

The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations.Semantic proximity Read ↗

Recent advances in the molecular understanding of glioblastoma.Semantic proximity Read ↗

Epigenetic Alterations in Glioblastoma Multiforme as Novel Therapeutic Targets: A Scoping ReviewSemantic proximity Read ↗

Predictive and Prognostic Significance of Molecular Biomarkers in GlioblastomaSemantic proximity Read ↗

Assessing <i>MGMT</i> methylation status and its current impact on treatment in glioblastomaSemantic proximity Read ↗

The DNA methylome of glioblastoma multiforme.Semantic proximity Read ↗

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?Semantic proximity Read ↗

Next Generation Sequencing and Machine Learning Technologies Are Painting the Epigenetic Portrait of GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.